.png){kind=icon}
.png){kind=icon}
Return
Nebulized amphotericin B deoxycholate in management of chronic pulmonary aspergillosis: experience from a tertiary care centre in North India
.png){kind=icon}
PRE
AI
I
R
V
S
K
S
A
M
A
DOI：10.1093/jac/dkag200.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Chronic pulmonary aspergillosis (CPA) requires prolonged oral azole therapy, yet 30%–40% experience relapse after treatment discontinuation. The role of nebulized amphotericin B (NAB) in CPA as a maintenance therapy remains unexplored.
Journal
IF:
3.6
Papers:
1.3W
Citations:
3.2W
Organization
Cited Papers